Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT00099437
Active, not recruiting Phase 3

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437 · tracked via the Priya Life Science Spain tracker
Sponsor
AstraZeneca
Phase
Phase 3
Started
2005-02-13
Last updated
2026-09-14

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

Fulvestrant →

Fulvestrant: intramuscular injection

Study summary

The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.

Eligibility

Sex
FEMALE
Min age
45 Years
Max age
130 Years
Healthy volunteers
No
Inclusion Criteria: * Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor * Requiring hormonal treatment * Postmenopausal women defined as a woman who has stopped having menstrual periods * Evidence of positive estrogen receptor hormone sensitivity * Written informed consent to participate in the trial Exclusion Criteria: * Treatment with an investigational or non-approved drug within one month * An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures * A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor oil) * Treatment with more than one regimen of chemotherapy for advanced breast cancer * Treatment with more than one regimen of hormonal treatment for advanced breast cancer

Primary outcome measure(s)

  • Time to Progression (TTP) — RECIST(Response Evaluation Criteria in Solid Tumors ) tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)
    Median time (in months) from randomisation until objective disease progression or death (in the absence of objective progression).

Trial sites (106)

FacilityCityRegionStatus
Research Site Casa Grande Arizona
Research Site Fountain Valley California
Research Site New Britain Connecticut
Research Site Crystal River Florida
Research Site Fort Lauderdale Florida
Research Site Urbana Illinois
Research Site Rosedale Maryland
Research Site Detroit Michigan
Research Site Kansas City Missouri
Research Site St Louis Missouri
Research Site Voorhees Township New Jersey
Research Site Greenville North Carolina
Research Site Pasadena Texas
Research Site West Bend Wisconsin
Research Site Brasschaat Belgium
Research Site Brussels Belgium
Research Site Brussels Belgium
Research Site Edegem Belgium
Research Site Ghent Belgium
Research Site Hasselt Belgium
Research Site Liège Belgium
Research Site Turnhout Belgium
Research Site Barretos Brazil
Research Site Londrina Brazil
Research Site Porto Alegre Brazil
Research Site Recife Brazil
Research Site Salvador Brazil
Research Site São Paulo Brazil
Research Site Antofagasta Chile
Research Site Santiago Chile
Research Site Santiago Chile
Research Site Bogotá Colombia
Research Site Cali Colombia
Research Site Brno Czechia
Research Site České Budějovice Czechia
Research Site Pardubice Czechia
Research Site Prague Czechia
Research Site Prague Czechia
Research Site Prague Czechia
Research Site Tábor Czechia

+ 66 more sites — see the full list on the official registry below.

More AstraZeneca trials in Spain

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations Active, not recruiting
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab Active, not recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT Recruiting
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer Active, not recruiting

Other trials for the same condition

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Recruiting
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. Active, not recruiting
Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer Recruiting
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions Recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00099437 on ClinicalTrials.gov ↗ ← All trials in Spain